Bendamustine in patients with relapsed or refractory multiple myeloma

por Michael, M, Bruns, I, Bölke, E, Zohren, F, Czibere, A, Safaian, N N, Neumann, F, Haas, R, Kobbe, G, Fenk, R
Publicado 2010

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022